GLP-1 Receptor Agonists' Expanding Role Demands Perioperative Vigilance from CRNAs
Background
The widespread use of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes mellitus and obesity has expanded to include off-label applications for substance use disorders, neurodegenerative diseases, and various cardiovascular, kidney, and liver diseases. This broad application means Certified Registered Nurse Anesthetists (CRNAs) frequently encounter patients on these medications. A critical gap exists in understanding the perioperative implications of GLP-1RAs, particularly concerning their impact on gastric motility and blood glucose control, which can significantly affect patient safety during anesthesia.
Study Design
This review synthesized current literature on GLP-1RAs pharmacology and mechanisms of action, specifically focusing on their relevance for Certified Registered Nurse Anesthetists (CRNAs) in the perioperative period. It explored the effects of GLP-1RAs on blood glucose control, gastric motility, and central nervous system pathways to inform safe anesthesia practice. The review also highlighted current professional guidelines emphasizing personalized, patient-centered perioperative care in the context of increasing GLP-1RA use, including off-label prescribing and unregulated peptide use.
Results
GLP-1RAs exert their effects through glucose-dependent insulin secretion and by reducing blood glucose fluctuations, offering significant metabolic benefits. However, a key perioperative concern is their propensity to cause delayed gastric emptying, which elevates the risk of pulmonary aspiration during anesthesia. The review emphasized that GLP-1RAs influence central nervous system pathways, contributing to their emerging roles beyond metabolic regulation. The expanding use, including off-label and unregulated peptide applications, underscores the critical need for comprehensive preoperative screening and accurate medication reconciliation. > Special attention must be given to delayed gastric emptying and the associated concerns about pulmonary aspiration in patients on GLP-1RAs. Effective interdisciplinary communication is paramount to optimize perioperative safety and achieve optimal patient outcomes in modern anesthesia practice.
Key Findings
- GLP-1RAs are widely used for diabetes and obesity, with expanding off-label applications for various conditions.
- GLP-1RAs cause delayed gastric emptying, increasing the risk of pulmonary aspiration during anesthesia.
- They improve blood glucose control through glucose-dependent insulin secretion and reduced fluctuations.
- Thorough preoperative screening and medication reconciliation are essential for patients on GLP-1RAs.
- Interdisciplinary communication is critical for optimizing perioperative safety with GLP-1RA users.
Why It Matters
For CRNAs and other anesthesia providers, this review highlights the critical need for enhanced vigilance and specific protocols when managing patients on GLP-1RAs. The risk of delayed gastric emptying means that standard NPO (nil per os) guidelines may be insufficient, potentially requiring extended fasting periods or alternative airway management strategies. Preoperative screening must explicitly inquire about GLP-1RA use, including off-label and unregulated peptides, to accurately assess aspiration risk. This information is crucial for tailoring anesthesia plans, ensuring patient safety, and preventing serious complications like aspiration pneumonitis. The evolving evidence base means continuous education is vital to adapt to new best practices.
glp-1ra
perioperative
anesthesia
gastric-emptying
aspiration
diabetes